Qiagen has entered into an agreement to transfer distribution rights for the Olerup sequence specific primer (SSP) product line and the related assets to Olerup International, a subsidiary of LinkMed.
According to the agreement, Qiagen will continue to have distribution rights to Olerup SSP products that can be used in applications outside transplantation testing.
The agreement also includes options for Qiagen to distribute future Olerup SSP assays for pharmacogenetic applications.
Through the transaction, Qiagen is expecting to increase its focus on the higher growth applications in transplantation testing such as sequencing-based typing, as well as the application of such assays in personalized medicine.
Peer Schatz, CEO of Qiagen, said: The agreement with LinkMed allows us to further execute our corporate strategy and streamline our portfolio.